Stocks Health care QNCX
NASDAQ · Health careQuince Therapeutics, Inc. (QNCX)
It posted a net loss of $92.5M. In fiscal 2025 capital spending exceeded operating cash flow by $41.8M. At June 30, 2026 it held $116M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Quince Therapeutics, Inc. does
Quince Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker QNCX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$84M | -$1.68 | -$41.8M |
| 2024 | n/a | -$56.8M | -$1.31 | -$32.2M |
| 2023 | n/a | -$31.4M | -$0.84 | -$18.5M |
| 2022 | n/a | -$51.7M | -$1.54 | -$44.2M |
| 2021 | n/a | -$89.9M | -$3.03 | -$63.1M |
| 2020 | n/a | -$76.8M | -$2.63 | -$50.9M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Quince Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 4, 2026
- August 27, 2026
- August 25, 2026Proxy statement DEF 14A
- August 17, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026
Insider trades
What the people running Quince Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns QNCX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Group One Trading LLC13G, passive | 10.7% | March 5, 2026 |
| David A. Lamond13D, may seek influence | 10.1% | November 13, 2024 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 9.99% | August 14, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 9% | August 14, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 7.2% | June 10, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 5.6% | August 4, 2026 |
Largest institutional holders
Insiders
Questions about QNCX
What does Quince Therapeutics, Inc. do?
Quince Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker QNCX.
Is Quince Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $92.5M.
When did Quince Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the acquisition or sale completed from September 14, 2026.
Similar companies
Compare QNCX with
Follow QNCX
Get an email when Quince Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow QNCX: get an email when it filesWhere the numbers come from
Financial figures are the values Quince Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.